ARF3 knockdown inhibits influenza a virus and virus-induced pneumonia
Zhinan Zhang1, Banghao Lu2, Bihe Zeng3
1Department of Pediatric Respiratory Medicine, Fujian Branch of Shanghai Children's Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Children's Hospital, Fujian Medical University, Fuzhou, 350000, Fujian, China.
Insights
ADP ribosylation factor 3 (ARF3) knockdown reduces lung injury and inflammation in influenza A virus pneumonia. Suppressing ARF3 inhibits viral replication and inflammasome activation, offering a potential therapeutic target.
Area of Science:
- Pulmonology
- Virology
- Immunology
Background:
- Pneumonia is a significant global health concern, especially in children.
- Influenza A virus (IAV) is a common cause of pneumonia.
- The role of ADP ribosylation factor 3 (ARF3) in IAV pneumonia is not well understood.
Purpose of the Study:
- To investigate the role of ARF3 in IAV-induced pneumonia.
- To evaluate ARF3 as a potential therapeutic target for pneumonia.
Main Methods:
- Utilized a young mouse model of IAV-induced pneumonia.
- Assessed ARF3 expression levels and the impact of ARF3 knockdown.
- Measured pro-inflammatory cytokine levels (TNF-α, IL-6, IL-1β).
- Performed in vitro experiments to assess IAV replication and NLRP3 inflammasome activation.
Main Results:
- ARF3 expression was upregulated in IAV-induced pneumonia.
- ARF3 knockdown mitigated lung injury and pulmonary inflammation.
- Suppression of ARF3 reduced pro-inflammatory cytokine levels.
- ARF3 downregulation inhibited H3N2 IAV replication and NLRP3 inflammasome activation.
Conclusions:
- ARF3 plays a critical role in IAV pneumonia pathogenesis.
- ARF3 knockdown demonstrates therapeutic potential by inhibiting viral replication and inflammation.
- Targeting ARF3 may offer a novel strategy for pneumonia treatment.
Abstract:
Pneumonia, characterized by infection-induced inflammation of the lungs, poses a significant health burden, particularly among children. ADP ribosylation factor 3 (ARF3) is a key regulatory protein implicated in various pathological processes; however, its role in pneumonia caused by influenza A virus (IAV) remains inadequately understood. In this study, we demonstrated that ARF3 expression was upregulated in a young mouse model of IAV-induced pneumonia. Knockdown of ARF3 effectively mitigated lung injury in this model. Furthermore, suppression of ARF3 expression alleviated pulmonary inflammation by reducing the levels of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β. In vitro experiments further revealed that ARF3 downregulation inhibited replication of the H3N2 IAV strain. Notably, ARF3 knockdown also attenuated NLRP3 inflammasome activation, a key mediator of inflammatory responses. Collectively, these findings provide the first evidence that ARF3 knockdown suppresses both IAV replication and virus-induced pneumonia by modulating inflammasome activation, suggesting that ARF3 may serve as a potential therapeutic target for pneumonia intervention.
